Abeona Therapeutics is rated a Hold, as Zevaskyn uptake and manufacturing remain uncertain, and its $135 million cash position could run out before 2028.
Krystal Biotech reported Q3 2026 net income of US$63.07 million with diluted EPS of US$2.05, beat consensus on earnings and revenue, and paired this with a new US$400 million share repurchase authorization that has no expiration date. The business leaned on continued VYJUVEK demand, including a 30% year over year revenue lift and progress on European pricing, while early KB113 data in Gorlin syndrome added pipeline depth alongside some timing shifts for other programs. We will now look at...
Krystal Biotech Inc (KRYS) posted strong double-digit Vyjuvek growth, authorized a $400 million share repurchase, and trimmed full-year expense guidance while advancing its pipeline.
Krystal Biotech stock fell after delaying pipeline data to 2027 despite a Q3 earnings beat. Read more here.
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here.
Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.
Krystal Biotech has produced a very large 5 year share price gain, which naturally puts the focus on whether that move is supported by the business it has built. With the stock now trading around US$324.57, the practical question for you is how well that market value lines up with the earnings the company is generating. A roughly 7x return over 5 years puts a lot of expectations into the price. The key issue is how firmly those expectations rest on current and future earnings power. The...
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market capitalization of
Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue. VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, or DEB, helps patients with an underlying genetic problem that leaves their skin extremely fragile and prone to chronic wounds. The […]
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization of
Krystal Biotech (KRYS) has an average rating of buy and mean price target of $386, according to anal
Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on September 04, 2026,
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This is the newest page. Registered accounts read further back.